Compare RMCO & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMCO | NEPH |
|---|---|---|
| Founded | 2021 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.0M | 31.0M |
| IPO Year | N/A | 2004 |
| Metric | RMCO | NEPH |
|---|---|---|
| Price | $2.79 | $2.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 31.3K | 20.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | $209.10 | $11.24 |
| Revenue Next Year | $133.33 | $11.58 |
| P/E Ratio | ★ N/A | $26.00 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.98 | $1.78 |
| 52 Week High | $5.00 | $6.42 |
| Indicator | RMCO | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 46.76 |
| Support Level | $2.80 | $2.79 |
| Resistance Level | $3.82 | $3.18 |
| Average True Range (ATR) | 0.27 | 0.20 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 54.24 | 64.48 |
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.